Clinical trials: Coronary Plaque Lipid Characterization
Coronary Plaque Lipid Characterization
Prospective Data Collection of IVMRI Cases
The study purpose is to prospectively collect data for a set of predefined variables in clinical cases where coronary plaque lipid characterization by IVMRI was performed during diagnostic or interventional procedures in order to…
- Trial name
- MIRACLE (NCT00558441)
- Testing
- IVMRI
- Where
- Israel
- Volunteers
- 1,000 people
- Sponsor
- TopSpin Medical
Angina Pectoris, Angina, Unstable
SPECTACL: SPECTroscopic Assessment of Coronary Lipid
The purpose of this study is to evaluate a near-infrared (NIR) spectroscopy system that has been designed to identify the chemical composition of coronary artery plaques in patients undergoing a percutaneous coronary intervention…
- Conditions
- Angina Pectoris, Angina, Unstable, Myocardial Infarction
- Trial name
- SPECTACL (NCT00330928)
- Testing
- Near Infrared Spectroscopy (NIRS) Imaging, intravascular ultrasound (IVUS)
- Where
- 6 sites in United States, Canada
- Volunteers
- 106 people
- Sponsor
- Infraredx
Coronary Artery Disease (CAD), Stable Angina Pectoris
Identification of Lesion Characteristics in Coronary Plaques Using Multimodality Intravascular Imaging and Novel Photon-counting CT in Stable Angina
Coronary artery disease, caused by the furring up of the heart arteries by atherosclerosis, is a major cause of death in the UK.
- Conditions
- Coronary Artery Disease (CAD), Stable Angina Pectoris, Ischaemic Heart Disease (IHD)
- Trial name
- ILUMINA (NCT07864025)
- Testing
- observational study
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- Queen Mary University of London
Acute Coronary Syndrome
Effects of Intensive Lipid Lowering and Omega-3 Fatty Acid on Composition of Coronary Atherosclerotic Plaque
The purpose of this study is to determine whether intensive lipid lowering and Omega-3 fatty acid are effective in the treatment of coronary atherosclerotic plaque.
- Trial name
- NCT00760786
- Testing
- Intensive lipid lowering plus Omega3-fatty acid, Moderate lipid lowering plus Omega3-fatty acid
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Samsung Medical Center